BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) dropped 3.8% during trading on Tuesday . The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares changed hands during trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Price Performance
The firm’s 50 day moving average price is C$10.60 and its two-hundred day moving average price is C$10.60. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. The stock has a market cap of C$168.68 million and a PE ratio of -28.19.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
